compound are made in a 96-well microtiter plate (Corning Costar 3695) using Solution 1. Following serial dilution each well has 50  $\mu$ l of Solution 1. The reaction is started by adding 50  $\mu$ l of solution 2 to each well. This may be done with a multichannel pipettor either manually or with automated liquid handling devices. The microtiter plate is then transferred to a microplate absorbance reader and multiple absorbance readings at 340 nm are taken for each well in a kinetic mode. The observed rate of change, which is proportional to the ATPase rate, is then plotted as a function of the compound concentration. For a standard IC<sub>50</sub> determination the data acquired is fit by the following four parameter equation using a nonlinear fitting program (e.g., Grafit 4):

$$y = \frac{\text{Range}}{1 + \left(\frac{x}{IC_{50}}\right)^s + \text{Background}}$$

where y is the observed rate and x is the compound concentration.

## 1-67. (canceled)

**68.** A method for the treatment of a cellular proliferative disease comprising administering to a subject in need thereof a pharmaceutical composition comprising a compound having the structure:

Formula I  $\begin{array}{c|c}
R_1 & R_5 \\
R_2 & R_7 \\
R_{12} & R_{13} & R_{14} \\
\end{array}$ 

and pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, prodrugs, and mixtures thereof, wherein:

R<sub>1</sub> is chosen from optionally substituted aryl-C<sub>1</sub>-C<sub>4</sub>-alkyland optionally substituted heteroaryl-C<sub>1</sub>-C<sub>4</sub>-alkyl-;

R<sub>2</sub> and R<sub>2</sub>, are independently chosen from hydrogen, optionally substituted alkyl-, optionally substituted alkoxy, optionally substituted aryl-, optionally substituted aralkyl-, optionally substituted heteroaryl-, and optionally substituted heteroaralkyl; or R<sub>2</sub> and R<sub>2</sub>, taken together form an optionally substituted 3- to 7-membered ring;

 $R_{12}$  is selected from the group consisting of optionally substituted imidazolyl, optionally substituted imidazolinyl, —NHR<sub>4</sub>; —N(R<sub>4</sub>)(COR<sub>3</sub>); —N(R<sub>4</sub>)(SO<sub>2</sub>R<sub>3a</sub>); and —N(R<sub>4</sub>)(CH<sub>2</sub>R<sub>3b</sub>);

R<sub>3</sub> is chosen from hydrogen, optionally substituted alkyl-, optionally substituted aryl-, optionally substituted aralkyl-, optionally substituted heteroaryl-, optionally substituted heteroaralkyl-, R<sub>15</sub>O— and R<sub>17</sub>—NH—;

 $R_{3a}$  is chosen from optionally substituted alkyl-, optionally substituted aryl-, optionally substituted aralkyl-, optionally substituted heteroaryl-, optionally substituted heteroaralkyl-, and  $R_{17}$ —NH—;

R<sub>3b</sub> is chosen from hydrogen, optionally substituted alkyl-, optionally substituted aryl-, optionally substituted aralkyl-, optionally substituted heteroaryl-, and optionally substituted heteroaralkyl;

 $R_4$  is chosen from hydrogen, optionally substituted alkyl-, optionally substituted aryl-, optionally substituted aralkyl-, optionally substituted hetercyclyl-, and optionally substituted heteroaralkyl-;

R<sub>5</sub>, R<sub>6</sub>, R<sub>7</sub> and R<sub>8</sub> are independently chosen from hydrogen, acyl, optionally substituted alkyl-, optionally substituted alkoxy, halogen, hydroxyl, nitro, cyano, dialkylamino, alkylsulfonyl-, alkylsulfonamido-, alkylthio-, carboxyalkyl-, carboxamido-, aminocarbonyl-, optionally substituted aryl and optionally substituted heteroaryl; and

 $R_{15}$  is chosen from optionally substituted alkyl-, optionally substituted aryl-, optionally substituted aralkyl-, optionally substituted heteroaryl-, and optionally substituted heteroaralkyl-,

R<sub>17</sub> is hydrogen, optionally substituted alkyl-, optionally substituted aryl-, optionally substituted aralkyl-, optionally substituted heteroaryl-, or optionally substituted heteroaralkyl-, including single stereoisomers, mixtures of stereoisomers.

**69.** A method according to claim 68, wherein if either  $R_2$  or  $R_2$  is hydrogen, then the other is not hydrogen.

**70.** A method according to claim 68 wherein  $R_5$ ,  $R_6$ ,  $R_7$  and  $R_8$  are each independently selected from hydrogen, amino, alkylamino, hydroxyl, halogen,  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  haloalkyl,  $C_1$ - $C_4$  alkoxy,  $C_1$ - $C_4$  haloalkoxy and cyano.

71. A method according to claim 70, wherein  $R_5$ ,  $R_6$ ,  $R_7$  and  $R_8$  are each independently selected from hydrogen, cyano, methoxy, and halogen.

**72**. A method according to claim 71, wherein  $R_5$ ,  $R_6$ , and  $R_8$  are each hydrogen and  $R_7$  is cyano, methoxy or halogen.

**73**. A method according to claim 68 or 69, wherein  $R_2$  is optionally substituted  $C_1$ - $C_4$  alkyl and  $R_2$  is hydrogen or optionally substituted  $C_1$ - $C_4$  alkyl.

**74.** A method according to claim 73, wherein  $R_2$  is hydrogen and  $R_2$  is optionally substituted  $C_1$ - $C_4$  alkyl.

**75.** A method according to claim 74, wherein  $R_2$  is hydrogen and  $R_2$  is ethyl or propyl.

76. A method according to claim 75, wherein  $R_2$  is i-propyl.

77. A method according to claim 68, wherein  $R_1$  is optionally substituted phenyl- $C_1$ - $C_4$ -alkyl- and optionally substituted naphthalenylmethyl.

**78.** A method according to claim 68, wherein  $R_1$  is benzyl, chlorobenzyl, methylbenzyl, methoxybenzyl, cyanobenzyl, hydroxybenzyl, dichlorobenzyl, dimethoxybenzyl, or naphthalenylmethyl.

**79**. A method according to claim 78, wherein  $R_1$  is benzyl-, cyanobenzyl-, methoxybenzyl-, or naphthalenylmethyl.

**80**. A method according to claim 79, wherein  $R_1$  is benzyl.

**81**. A method according to claim 68, wherein  $R_{12}$  is — $N(R_4)(COR_3)$  and  $R_3$  is selected from optionally substituted alkyl-, optionally substituted aralkyl-, optionally sub-